Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

Summary

This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.

Timeline

Start

2024-08-28

Primary completion

2027-08-30

Completion

2032-08-30

Drugs

Indications